|Application ||WB, IHC, E|
|Calculated MW||61128 Da|
|Description||The CD19 antigen (95kDa) is expressed from the earliest stage of B progenitor development, on all peripheral B cells including germinal centre B cells, and all B cell lines and B cell leukaemia tested. T cell and monocytic cell lines are negative and the antigen is lost on B cell maturation to plasma cells. The antigen is a type I integral membrane glycoprotein whose in vitro inhibition will influence B cell activation and proliferation.|
|Immunogen||Purified recombinant fragment of human CD19 expressed in E. Coli.|
|Formulation||Purified antibody in PBS containing 0.03% sodium azide.|
|Other Names||B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12, CD19, CD19|
|Dilution||WB~~1/500 - 1/2000|
IHC~~1/200 - 1/1000
|Precautions||CD19 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Assembles with the antigen receptor of B-lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.|
|Cellular Location||Membrane; Single-pass type I membrane protein|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1. Rie, M.A. de, J. of Immunol. Methods, 1987. 102: 187. 2. Rie, M.A. de, Leukaemia Research, 1988. 12: 135.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.